Renalytix plc (RNLXY): R&D Expense
Not updated since 2024-06-30. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
$9.29M
Year ended 2024-06-30
-2.6%
3-year compound annual growth
+16.6%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2024-06-30 | $9.29M | -35.0% | 2024-09-30, From 2023-07-01 |
| 2023-06-30 | $14.30M | -2.4% | 2024-09-30, From 2022-07-01 |
| 2022-06-30 | $14.65M | +45.9% | 2023-09-28, From 2021-07-01 |
| 2021-06-30 | $10.04M | +119.9% | 2022-10-31, From 2020-07-01 |
| 2020-06-30 | $4.57M | +5.8% | 2022-10-31, From 2019-07-01 |
| 2019-06-30 | $4.32M | n/a | 2022-08-01, From 2018-07-01 |